Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.

[img]
Preview
Text
PIIS0022202X17330683.pdf - Published Version

Download (694kB) | Preview

Abstract

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse events or ineffectiveness in patients with psoriasis who had failed a first biologic therapy and switched to a second in a large, multicenter pharmacovigilance registry (n = 1,239; adalimumab, n = 538; etanercept, n = 104; ustekinumab, n = 597). The overall drug survival rate in the first year after switching was 77% (95% confidence interval = 74-79%), falling to 58% (55-61%) in the third year. Female sex, multiple comorbidities, concomitant therapy with cyclosporine, and a high Psoriasis Area and Severity Index at switching to the second-line biologic therapy were predictors of overall discontinuation (multivariable Cox proportional hazard model). Compared to adalimumab, patients receiving etanercept were more likely to discontinue therapy (hazard ratio = 1.87, 95% confidence interval = 1.24-2.83), whereas patients receiving ustekinumab were more likely to persist (hazard ratio = 0.46; 95% confidence interval = 0.33-0.64). Discontinuation of the first biologic therapy because of adverse events was associated with an increased rate of second drug discontinuation because of adverse events (hazard ratio = 2.55; 95% confidence interval = 1.50-4.32). In conclusion, drug survival rates differed among biologic therapies and decreased over time; second-line discontinuation because of adverse events was more common among those who discontinued first-line treatment for this reason. The results of this study should support clinical decision making when choosing second-line biologic therapy for patients with psoriasis.

Item Type: Article
Additional Information: The final version of this article and all relevant information regarding copyrights and more can be found at; https://www.jidonline.org/article/S0022-202X(17)33068-3/fulltext#articleInformation https://www.sciencedirect.com/science/article/pii/S0022202X17330683
Subjects: Q Science > Q Science (General)
R Medicine > R Medicine (General)
R Medicine > RC Internal medicine
R Medicine > RL Dermatology
Divisions: Faculty of Medicine and Health Sciences > School of Medicine
Related URLs:
Depositing User: Symplectic
Date Deposited: 11 Aug 2020 12:13
Last Modified: 11 Aug 2020 12:13
URI: https://eprints.keele.ac.uk/id/eprint/8506

Actions (login required)

View Item View Item